pharma · Advanced Cancer · Advanced Solid Tumors · TCRT
Alaunos Therapeutics is a pharma organization headquartered in Houston, USA. It trades on NYSE under ticker TCRT. Primary therapeutic focus areas include Advanced Cancer, Advanced Solid Tumors, Solid Tumors, Melanoma, Me
Phase 1 · small molecule · Lymphoma
Alaunos Therapeutics is developing an IL-2 program (internal code 2007-0635) for lymphoma treatment using acetylcysteine as the active pharmaceutical ingredient. The program is formulated as an oral small-molecule therapy and has completed Phase 1 clinical evaluation as of December 2023. Acetylcysteine is an establishe
Internal code 2007-0635
Alaunos Therapeutics is developing an IL-2 program (internal code 2007-0635) for lymphoma treatment using acetylcysteine as the active pharmaceutical ingredient. The program is formulated as an oral small-molecule therapy and has completed Phase 1 clinical evaluation as of December 2023. Acetylcysteine is an established pharmaceutical agent with multiple FDA approvals across numerous generic manufacturers, indicating a well-characterized safety and pharmacokinetic profile. The IL-2 program represents Alaunos' investigational application of this repurposed agent in the lymphoma indication. The Phase 1 trial (NCT00968760) has concluded, though detailed efficacy and safety results from this stage remain undisclosed. The program's current development trajectory and plans for advancement to subsequent clinical phases have not been publicly announced. Acetylcysteine's existing regulatory approvals in the United States provide a foundation for potential expedited development pathways, though the specific regulatory strategy for the lymphoma indication is not yet disclosed.
Lymphoma remains a significant oncologic disease area with substantial unmet medical need despite the availability of approved therapies. The competitive landscape includes multiple approved agents spanning diverse mechanisms—from traditional chemotherapy (etoposide) to targeted small molecules (ibrutinib, crizotinib, temsirolimus) to immunoconjugates (brentuximab vedotin, ONTAK). Repurposing established pharmaceutical agents for oncologic indications offers potential advantages including reduced development timelines, known safety profiles, and lower clinical development costs compared to novel chemical entities. Acetylcysteine's antioxidant and immunomodulatory properties may provide a distinct mechanistic approach within the crowded lymphoma treatment landscape. The patient population for lymphoma spans multiple subtypes and disease stages, creating opportunities for targeted positioning. However, the program's competitive positioning relative to approved agents and emerging Phase 3 candidates (E7777, pirtobrutinib/ibrutinib combinations, rituximab-based regimens) will depend on demonstrated clinical efficacy, safety advantages, and convenience factors. The completion of Phase 1 represents a critical inflection point; advancement to Phase 2 would signal sponsor confidence in the therapeutic hypothesis and clinical viability of this repurposed approach in lymphoma.
Drug Class: Antioxidant/immunomodulatory small molecule
Active Ingredient: Acetylcysteine (N-acetyl-L-cysteine)
Modality: Small-molecule oral therapy
Route of Administration: Oral
Mechanism of Action: Not yet disclosed for the IL-2 lymphoma program
Target: Not yet disclosed
Regulatory Status (Acetylcysteine): FDA-approved; multiple generic formulations available from 21 manufacturers including Alvogen, Cumberland Pharmaceuticals, Hospira, Roxane, and others across numerous ANDA and NDA applications
Related Therapies in Lymphoma: Approved agents include ibrutinib (Bruton tyrosine kinase inhibitor), brentuximab vedotin (CD30-directed immunoconjugate), temsirolimus (mTOR inhibitor), and ONTAK (denileukin difitox, IL-2 fusion protein)
Also known as: lymphoma (Hodgkin and non-Hodgkin), lymphoma (Hodgkin's and non-Hodgkin's), lymphoma, malignant, lymphomatous, malignant lymphoma, MLYM
A malignant (clonal) proliferation of B- lymphocytes or T- lymphocytes which involves the lymph nodes, bone marrow and/or extranodal sites. This category includes Non-Hodgkin lymphomas and Hodgkin lymphomas.
ClinicalTrials.gov lists 16 registered studies for Lymphoma, Hodgkin (AACT aggregate).
Phase breakdown: NA (10), PHASE1 (3), PHASE2 (3)
Common investigational therapies:
Disease data sourced from MONDO Disease Ontology (MONDO:0005062), Orphanet — lymphoma, NCT00026208, NCT00578461, NCT01459224, NCT02996773, NCT03117036, AACT (ClinicalTrials.gov aggregate), ClinicalTrials.gov, Open Targets Platform (CC BY 4.0).
Phase 1 completion
Phase 1 trial (NCT00968760) completed; detailed results not yet disclosed.
The lymphoma treatment landscape includes multiple approved small-molecule and biologic therapies with distinct mechanisms. Ibrutinib (AbbVie), a Bruton tyrosine kinase inhibitor, represents a standard-of-care option for certain lymphoma subtypes. Brentuximab vedotin (Takeda), a CD30-directed antibody-drug conjugate, provides an immunoconjugate approach. Temsirolimus (Pfizer) targets mTOR signaling. ONTAK (denileukin difitox, Ligand Pharmaceuticals) is an IL-2 fusion protein, representing a direct IL-2 pathway therapeutic precedent in lymphoma. Traditional chemotherapy agents including etoposide remain in use. Emerging Phase 3 candidates include E7777 (9 mcg/kg, Citius Oncology), pirtobrutinib and ibrutinib combinations (Wuhan Createrna), and rituximab-based regimens with gemcitabine and oxaliplatin (Hoffmann-La Roche). The Alaunos IL-2 program using oral acetylcysteine would need to demonstrate clinical advantages in efficacy, safety, tolerability, or convenience relative to these established and emerging options to establish competitive positioning.
| Therapy | Company | Mechanism | Status |
|---|---|---|---|
| Etoposide | Xiyuan Hospital of China Academy of Chinese Medical Sciences | small_molecule | approved |
| Ibrutinib | AbbVie Deutschland GmbH & Co. KG | small_molecule | approved |
| Brentuximab vedotin | Takeda | small_molecule | approved |
| crizotinib | Xiyuan Hospital of China Academy of Chinese Medical Sciences | small_molecule | approved |
| ONTAK (denileukin difitox, DAB389IL-2) | LIGAND PHARMACEUTICALS INC | small_molecule | approved |
| temsirolimus | Pfizer | small_molecule | approved |
| AMOXICILLIN TRIHYDRATE, SULFAMETHOXAZOLE AND TRIMETHOPRIM , LEVOFLOXACIN, AMOXICILLIN , AZITHROMYCIN, AZITHROMYCIN , IMMUNOGLOBULINS, NORMAL HUMAN, FOR INTRAVASCULAR ADM., LEVOFLOXACIN | Pari Pharma GmbH | small_molecule | phase_3 |
| Ondansetron Aurobindo 8 mg Filmtabletten, Zarzio 48 MU/0.5 ml solution for injection or infusion in pre-filled syringe, Rixathon 500 mg concentrate for solution for infusion, Zarzio 48 MU/0.5 ml solution for injection or infusion in pre-filled syringe, Rixathon 500 mg concentrate for solution for infusion, Cisplatin 1 mg/ml Concentrate for Solution for Infusion, Dexametazona Krka 4 mg comprimate, EMEND 125 mg+80 mg hard capsules, Carboplatin Hikma 10 mg/ml Konzentrat zur Herstellung einer Infusionslösung, G | Karyopharm Therapeutics Inc | small_molecule | phase_3 |
| PIRTOBRUTINIB, IBRUTINIB, PIRTOBRUTINIB, IBRUTINIB | Wuhan Createrna Science and Technology Co., Ltd | small_molecule | phase_3 |
| E7777 9 mcg/kg | CITIUS ONCOLOGY, INC. | small_molecule | phase_3 |
| MabThera 500 mg concentrate for solution for infusion, Polivy 140 mg powder for concentrate for solution for infusion., GEMCITABINE , OXALIPLATIN | Hoffmann-La Roche | small_molecule | phase_3 |
| ZOLEDRONIC ACID | — | Farnesyl diphosphate synthase inhibitor | Approved |
| ZANUBRUTINIB | — | Tyrosine-protein kinase BTK inhibitor | Approved |
| VORINOSTAT | — | Histone deacetylase 1 inhibitor | Approved |
| VINBLASTINE SULFATE | — | Tubulin inhibitor | Approved |
| VENETOCLAX | — | Apoptosis regulator Bcl-2 inhibitor | Approved |
| UMBRALISIB TOSYLATE | — | Tyrosine-protein kinase ABL inhibitor | Approved |
| TISAGENLECLEUCEL | — | B-lymphocyte antigen CD19 binding agent | Approved |
| THALIDOMIDE | — | CRL4(CRBN) E3 ubiquitin ligase inhibitor | Approved |
| TECLISTAMAB | — | Tumor necrosis factor receptor superfamily member 17 binding agent | Approved |
Additional associated therapies sourced from Open Targets Platform (CC0), linked to NovaPharmaNews drug profiles where matched.
United States: Acetylcysteine is FDA-approved with multiple generic manufacturers holding ANDAs and NDAs. The IL-2 program for lymphoma indication represents an investigational use of this approved agent. Regulatory pathway and approval strategy for the lymphoma indication not yet disclosed.
European Union, Japan (PMDA), China (NMPA): Regulatory status for the IL-2 lymphoma program in these jurisdictions not yet disclosed.
Patent Status: Not yet disclosed.
Expected Loss of Exclusivity: Not yet disclosed for the IL-2 program formulation.
It is an investigational oral small-molecule therapy using acetylcysteine for lymphoma treatment, currently in completed Phase 1 development.
No, the program has completed Phase 1 trials but is not yet approved. Acetylcysteine itself is FDA-approved as a generic medication for other indications.
Acetylcysteine (N-acetyl-L-cysteine), an antioxidant small molecule administered orally.
The specific mechanism of action for the IL-2 program in lymphoma has not been disclosed by Alaunos.
Alaunos Therapeutics is the sponsor; no development partner has been disclosed.
NCT00968760 is a Phase 1 trial that completed in December 2023; detailed results have not yet been reported.
Phase 1 is complete as of December 19, 2023. Plans for Phase 2 advancement and timelines have not been announced.
The specific lymphoma subtypes targeted by the program have not been disclosed.
Yes, acetylcysteine is FDA-approved and available as a generic medication from over 20 manufacturers for established indications.
Approved competitors include ibrutinib, brentuximab vedotin, temsirolimus, and ONTAK; Phase 3 candidates include E7777 and rituximab-based combinations.
The IL-2 program is formulated for oral administration.
Any regulatory designations (fast track, breakthrough therapy, etc.) have not been disclosed.
Peak sales projections have not been disclosed.
No development partner has been disclosed; Alaunos is the sole sponsor.
Expected Phase 2 initiation date and result timelines have not been announced.
Patent status and exclusivity strategy for the IL-2 program formulation have not been disclosed.
IL-2 → Drug → Target → Indication → Company → Trials → Competitors
Strategic Implications: Alaunos' selection of acetylcysteine for lymphoma represents a repurposing strategy leveraging an established pharmaceutical with known safety and pharmacokinetic properties. This approach may enable faster development timelines and lower clinical costs compared to novel entities, though efficacy in lymphoma must be demonstrated.
Competitive Implications: The program enters a mature, competitive lymphoma market with multiple approved options and Phase 3 candidates. Success will require differentiation through superior efficacy, improved safety profile, enhanced convenience (oral administration), or favorable cost-effectiveness relative to existing standards and emerging therapies.
Development Catalysts: Advancement to Phase 2 would represent the critical next milestone, requiring demonstration of clinical activity and acceptable tolerability in the Phase 1 cohort. Publication of Phase 1 results would provide transparency regarding dose escalation, safety signals, and preliminary efficacy indicators.
Unresolved Questions: The mechanism of action for acetylcysteine in lymphoma remains undisclosed. The specific lymphoma subtypes targeted, patient population characteristics, and comparator strategy for Phase 2 are not yet announced. Regulatory pathway designation (if any) and partnership discussions remain unknown.
Concise, citable answers optimized for AI answer engines.
Intelligence compiled from public regulatory and clinical sources (FDA, EMA, ClinicalTrials.gov and company disclosures). Figures may be editorial or analyst estimates; verify against primary sources before relying on them.